Ezetimibe

Green-G

Brand Name(s):Ezetrol

Indication:Primary Hypercholesterolaemia, prevention of cardiovascular events, Homozygous Familial Hypercholesterolaemia (HoFH)

Rationale:

Considered:Apr-07

Review Date:Oct-26

Comments:
NICE TA694 1.1 Bempedoic acid with ezetimibe is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if: statins are contraindicated or not tolerated, ezetimibe alone does not control low-density lipoprotein cholesterol well enough and the company provides bempedoic acid and bempedoic acid with ezetimibe according to the commercial arrangement.

Bempedoic acid with ezetimibe can be used as separate tablets or a fixed-dose combination.

1.2 This recommendation is not intended to affect treatment with bempedoic acid with ezetimibe that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. NICE CG71 (update) Familial hypercholesterolaemia: identification and management
July 2016
…………………………
NICE TA385
February 2016

NICE TA 132
January 2007